UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

19 Mar, 2021

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
Photo by Markus Spiske on Unsplash

– UroGen Pharma Ltd. (Nasdaq: URGN) entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (“RTW”).
– Under the terms of the agreement, subject to customary closing conditions, UroGen will receive $75m in upfront cash from RTW in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto® (mitomycin) for pyelocalyceal solution as well as UGN-102, if approved.

Biopharma Biotechnology Clinical Trials Life Science North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: